Visual Prognosis of Multifocal Choroiditis, Punctate Inner Choroidopathy, and the Diffuse Subretinal Fibrosis Syndrome

Brown, Jeremiah; Folk, James C.; Reddy, Chittaranjan V.; Kimura, Alan

doi:10.1016/s0161-6420(96)30561-7

Cited by 177 publications

(117 citation statements)

References 12 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Within this group of inflammatory diseases, CNV is a major sight-threatening complication, and patients with subfoveal CNV have the most guarded prognosis. 55,56 Therapeutic options Subfoveal CNV in various inflammatory chorioretinal disorders often responds to systemic, 57 periocular, or intraocular corticosteroid therapy. When this approach Intravitreal bevacizumab for non-AMD choroidal neovascularisation B Gupta et al…”

Section: Inflammatory Eye Diseasementioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

Section: Inflammatory Eye Diseasementioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

show abstract

“…After follow-up for 12 months, the mean VA was maintained at 39 letters, which is far better than the natural history of the condition if untreated. 1,2 …”

Section: Discussionmentioning

confidence: 99%

“…2 Patients with subfoveal CNV have the worst prognosis and in most cases, the visual acuity (VA) decreases to 6/60 or worse, even with treatment. 2,3 In inflammatory chorioretinal diseases like presumed ocular histoplasmosis syndrome (POHS) that behave and present like PIC, other therapeutic strategies like thermal laser 4 and surgical CNV extraction 5 have been used with limited benefit and a high recurrence rate, 6 for example, up to 44% after surgical CNV removal. 7 Previous studies have reported some good results in patients treated with intensive high-dose immunosuppression but recurrence of the CNV and visual loss can occur when the immunosuppression therapy is reduced.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy

Fong

Thomas

Amin

et al. 2007

Eye

View full text Add to dashboard Cite

Aim To report on visual acuity (VA) and angiographic outcomes in patients presenting with subfoveal choroidal neovascular membranes (CNV) secondary to punctate inner choroidopathy (PIC), treated with photodynamic therapy (PDT) with verteporfin combined with systemic corticosteroids. Methods A prospective case series of patients with subfoveal CNV secondary to PIC was analysed. All patients were treated with PDT combined with oral prednisolone (1 mg/kg body weight/day) which was started 5 days before PDT. Fluorescein angiography was performed at baseline and every 3 months post-treatment to establish the size, position, and activity of the CNV. Visual acuity was measured using the ETDRS scale. Further PDT treatment was carried out at follow-up visits if there was angiographic evidence of ongoing CNV activity. Results Five female patients with a mean age of 30.4 years (range 25-43 years) were treated over a 12-month period. The mean greatest linear diameter (GLD) of the CNV was 1.66 mm (range 0.46-3.28 mm). A mean improvement in vision of nine ETDRS letters (range À15-20 letters) after treatment was found, which was maintained at final followup. The mean follow-up time was 12 months (range 10-14 months). The mean number of PDT treatments was two (range 1-3). Conclusions: The vaso-occlusive effect of PDT combined with the vasostatic and antiinflammatory effect of systemic oral prednisolone appears to be a safe and effective option in the primary treatment of subfoveal CNV in patients with PIC.

show abstract

“…Causes of decreased vision include fl oaters and vitritis in the acute stage, cystoid macular edema (CME), exudation due to choroidal neovascularization, ERM formation & fi brotic macular scars in the atrophic stage. 10 Peripheral visual fi eld loss not corresponding to the extent of choroiditis may also develop.…”

Section: Multifocal Choroiditis and Panuveitismentioning

confidence: 99%

White Dot Syndromes

Biswas¹

2015

DJO

View full text Add to dashboard Cite

show abstract

Visual Prognosis of Multifocal Choroiditis, Punctate Inner Choroidopathy, and the Diffuse Subretinal Fibrosis Syndrome

Cited by 177 publications

References 12 publications

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy

White Dot Syndromes

Contact Info

Product

Resources

About